Drug Approval | December 28, 2024
Shilpa Medicare's Unit IV receives Eurasia GMP approval
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
This approval is a significant achievement in expanding the availability of this critical therapeutic,
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Exploring new opportunities within the fast-growing market of microfluidics
Divestment is part of BASF’s strategic portfolio optimization
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
The company has received the GMP Certification after successful closure of the inspection
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Subscribe To Our Newsletter & Stay Updated
